| ファイル情報(添付) | |
| タイトル |
Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib.
|
| 著者 |
Okimoto Tamio
|
| 収録物名 |
Internal medicine
|
| 巻 | 59 |
| 号 | 2 |
| 開始ページ | 253 |
| 終了ページ | 256 |
| 収録物識別子 |
ISSN 0918-2918
EISSN 1349-7235
|
| 内容記述 |
その他
A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with ceritinib as a fifth-line treatment. On day 54 after rechallenge, the patient developed acutely deteriorating dyspnea. Chest computed tomography showed extensive ground-glass opacities. We diagnosed him with ceritinib-induced interstitial lung disease (ILD) and initiated methylprednisolone pulse therapy. To our knowledge, this is the first report of ceritinib-induced ILD in a Japanese patient. Since it may newly emerge with rechallenge therapy, close attention is necessary.
|
| 主題 |
ceritinib
interstitial lung disease
anaplastic lymphoma kinase
adverse event
|
| 言語 |
英語
|
| 資源タイプ | 学術雑誌論文 |
| 出版者 |
一般社団法人 日本内科学会
The Japanese Society of Internal Medicine
|
| 発行日 | 2019 |
| 出版タイプ | Accepted Manuscript（出版雑誌の一論文として受付されたもの。内容とレイアウトは出版社の投稿様式に沿ったもの） |
| アクセス権 | オープンアクセス |
| 関連情報 |
イッパン シャダンホウジン ニホン ナイカ ガッカイ
|
